ANCA-associated vasculitis.

Area of Science:

• Immunology
• Rheumatology
• Pathology

Background:

• ANCA-associated vasculitides (AAVs) are systemic small-vessel diseases characterized by autoantibodies to neutrophil proteins, PR3-ANCA or MPO-ANCA.
• Current AAV classification includes GPA, MPA, and EGPA, but alternative classifications based on PR3-AAV, MPO-AAV, and ANCA status in EGPA are proposed.
• AAVs commonly affect the respiratory tract and kidneys, with complex pathogenesis involving ANCA-mediated neutrophil activation and T cell involvement.

Purpose of the Study:

• To review the current understanding of ANCA-associated vasculitides (AAVs).
• To discuss the classification, pathogenesis, and clinical manifestations of AAVs.
• To highlight current challenges and future directions in AAV research and treatment.

Main Methods:

• Literature review of ANCA-associated vasculitides.
• Analysis of existing data on AAV classification and pathogenesis.
• Discussion of current therapeutic strategies and unmet needs in AAV management.

Main Results:

• AAVs are classified by ANCA type (PR3 or MPO) and clinical presentation, with proposed alternative classifications.
• The pathogenesis involves a loss of tolerance to neutrophil proteins, leading to ANCA-mediated inflammation.
• While immunosuppressants improve survival, significant morbidity and challenges in disease management persist.

Conclusions:

• A deeper understanding of AAV biology is needed to address challenges in disease activity measurement, relapse risk, and therapy optimization.
• Future research should focus on developing targeted therapies with fewer adverse effects.
• International collaboration and patient input are essential for advancing AAV care.